Loading…

Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy

Background Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies. Purpose To evaluate the prognostic v...

Full description

Saved in:
Bibliographic Details
Published in:Acta radiologica (1987) 2011-07, Vol.52 (6), p.646-650
Main Authors: Yan, Hongjiang, Wang, Renben, Zhao, Fen, Zhu, Kunli, Jiang, Shumei, Zhao, Wei, Feng, Rui
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703
cites cdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703
container_end_page 650
container_issue 6
container_start_page 646
container_title Acta radiologica (1987)
container_volume 52
creator Yan, Hongjiang
Wang, Renben
Zhao, Fen
Zhu, Kunli
Jiang, Shumei
Zhao, Wei
Feng, Rui
description Background Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies. Purpose To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC. Material and Methods We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used. Results In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax. Conclusion MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC.
doi_str_mv 10.1258/ar.2011.100462
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_874483565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1258_ar.2011.100462</sage_id><sourcerecordid>874483565</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</originalsourceid><addsrcrecordid>eNp1kTuP1DAUhS0EYoeFlhK5QRQow3Vs51Gi1fKQFkGx1NGNczObVWIPfsxqfgT_GYcZoKKxC3_n-N5zGHspYCtK3bxDvy1BiK0AUFX5iG1EBVCA0vox20DZqEI0WlywZyHcA4iy1uIpuyiFhibrNuznF8KQPC1kI3cjj2lxnh_cnBbi_ZF_u77l0XE64JwwEt97t7MuTIFPlu8xTlkX-MMU7zgOB7SGBm6dLcKC88wN5WNOdsfN-uR59JRdhtX5N5X8bjI483hHHvfH5-zJiHOgF-f7kn3_cH179am4-frx89X7m8LICmIxYE_YS23q2tQtjjCWRtW9KqWqDIyyVShRjKRkrRSJFqp-UFS1Yzs0va5BXrI3J9-8zo9EIXbLFNZh0ZJLoWuyrpG60pncnkjjXQiexm7vpwX9sRPQrQ106Lu1ge7UQBa8OlunfqHhL_4n8gy8PgMY8uqjz8lM4R-nJFTQqMy9PXEBd9Tdu-RtjuR_3_4Cc5Od-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>874483565</pqid></control><display><type>article</type><title>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</title><source>Sage Journals Online</source><creator>Yan, Hongjiang ; Wang, Renben ; Zhao, Fen ; Zhu, Kunli ; Jiang, Shumei ; Zhao, Wei ; Feng, Rui</creator><creatorcontrib>Yan, Hongjiang ; Wang, Renben ; Zhao, Fen ; Zhu, Kunli ; Jiang, Shumei ; Zhao, Wei ; Feng, Rui</creatorcontrib><description>Background Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies. Purpose To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC. Material and Methods We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used. Results In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax. Conclusion MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC.</description><identifier>ISSN: 0284-1851</identifier><identifier>EISSN: 1600-0455</identifier><identifier>DOI: 10.1258/ar.2011.100462</identifier><identifier>PMID: 21508201</identifier><identifier>CODEN: ACRAE3</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Area Under Curve ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - therapy ; Female ; Fluorodeoxyglucose F18 ; Humans ; Image Interpretation, Computer-Assisted ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Medical sciences ; Neoplasm Staging ; Pneumology ; Positron-Emission Tomography - methods ; Prognosis ; Radiopharmaceuticals ; Retrospective Studies ; ROC Curve ; Survival Rate ; Tumor Burden ; Tumors of the respiratory system and mediastinum</subject><ispartof>Acta radiologica (1987), 2011-07, Vol.52 (6), p.646-650</ispartof><rights>2011 The Foundation Acta Radiologica</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</citedby><cites>FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24306084$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21508201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Zhao, Fen</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><title>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</title><title>Acta radiologica (1987)</title><addtitle>Acta Radiol</addtitle><description>Background Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies. Purpose To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC. Material and Methods We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used. Results In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax. Conclusion MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC.</description><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Image Interpretation, Computer-Assisted</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Staging</subject><subject>Pneumology</subject><subject>Positron-Emission Tomography - methods</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>ROC Curve</subject><subject>Survival Rate</subject><subject>Tumor Burden</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0284-1851</issn><issn>1600-0455</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kTuP1DAUhS0EYoeFlhK5QRQow3Vs51Gi1fKQFkGx1NGNczObVWIPfsxqfgT_GYcZoKKxC3_n-N5zGHspYCtK3bxDvy1BiK0AUFX5iG1EBVCA0vox20DZqEI0WlywZyHcA4iy1uIpuyiFhibrNuznF8KQPC1kI3cjj2lxnh_cnBbi_ZF_u77l0XE64JwwEt97t7MuTIFPlu8xTlkX-MMU7zgOB7SGBm6dLcKC88wN5WNOdsfN-uR59JRdhtX5N5X8bjI483hHHvfH5-zJiHOgF-f7kn3_cH179am4-frx89X7m8LICmIxYE_YS23q2tQtjjCWRtW9KqWqDIyyVShRjKRkrRSJFqp-UFS1Yzs0va5BXrI3J9-8zo9EIXbLFNZh0ZJLoWuyrpG60pncnkjjXQiexm7vpwX9sRPQrQ106Lu1ge7UQBa8OlunfqHhL_4n8gy8PgMY8uqjz8lM4R-nJFTQqMy9PXEBd9Tdu-RtjuR_3_4Cc5Od-g</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Yan, Hongjiang</creator><creator>Wang, Renben</creator><creator>Zhao, Fen</creator><creator>Zhu, Kunli</creator><creator>Jiang, Shumei</creator><creator>Zhao, Wei</creator><creator>Feng, Rui</creator><general>SAGE Publications</general><general>Royal Society of Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</title><author>Yan, Hongjiang ; Wang, Renben ; Zhao, Fen ; Zhu, Kunli ; Jiang, Shumei ; Zhao, Wei ; Feng, Rui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Image Interpretation, Computer-Assisted</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Staging</topic><topic>Pneumology</topic><topic>Positron-Emission Tomography - methods</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>ROC Curve</topic><topic>Survival Rate</topic><topic>Tumor Burden</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Zhao, Fen</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta radiologica (1987)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Hongjiang</au><au>Wang, Renben</au><au>Zhao, Fen</au><au>Zhu, Kunli</au><au>Jiang, Shumei</au><au>Zhao, Wei</au><au>Feng, Rui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</atitle><jtitle>Acta radiologica (1987)</jtitle><addtitle>Acta Radiol</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>52</volume><issue>6</issue><spage>646</spage><epage>650</epage><pages>646-650</pages><issn>0284-1851</issn><eissn>1600-0455</eissn><coden>ACRAE3</coden><abstract>Background Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies. Purpose To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC. Material and Methods We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used. Results In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax. Conclusion MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21508201</pmid><doi>10.1258/ar.2011.100462</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0284-1851
ispartof Acta radiologica (1987), 2011-07, Vol.52 (6), p.646-650
issn 0284-1851
1600-0455
language eng
recordid cdi_proquest_miscellaneous_874483565
source Sage Journals Online
subjects Area Under Curve
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - diagnostic imaging
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Female
Fluorodeoxyglucose F18
Humans
Image Interpretation, Computer-Assisted
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Medical sciences
Neoplasm Staging
Pneumology
Positron-Emission Tomography - methods
Prognosis
Radiopharmaceuticals
Retrospective Studies
ROC Curve
Survival Rate
Tumor Burden
Tumors of the respiratory system and mediastinum
title Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T01%3A11%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20of%20tumor%20volume%20by%20PET%20to%20evaluate%20prognosis%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20treated%20by%20non-surgical%20therapy&rft.jtitle=Acta%20radiologica%20(1987)&rft.au=Yan,%20Hongjiang&rft.date=2011-07-01&rft.volume=52&rft.issue=6&rft.spage=646&rft.epage=650&rft.pages=646-650&rft.issn=0284-1851&rft.eissn=1600-0455&rft.coden=ACRAE3&rft_id=info:doi/10.1258/ar.2011.100462&rft_dat=%3Cproquest_cross%3E874483565%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=874483565&rft_id=info:pmid/21508201&rft_sage_id=10.1258_ar.2011.100462&rfr_iscdi=true